Blinatumomab (Anatumomab) 是一种双特异性单克隆抗体，有两个结合位点，分别是 T 细胞表面的 CD3E 和 B 细胞表面的 CD19。Blinatumomab 可用于急性淋巴细胞白血病的研究。

For Powder, reconstitute with sterile, distilled water to a final concentration of 1 mg/ml. Gently shake to solubilize completely. Do not vortex.

本产品仅用作科学研究！

The detected molecular weight of Anti-CD19 & CD3 Reference Antibody (Blinatumomab) is 53.81 kDa.

Anti-CD19 & CD3 Reference Antibody (Blinatumomab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

The purity of Anti-CD19 & CD3 Reference Antibody (Blinatumomab) is 98.26%, determined by SEC-HPLC.

Blinatumomab bound to CD19 protein, and then rebounded to secondary antibodies(Anti-6*his-HRP ) , and read OD450. As shown in fig, Blinatumomab bound to in human CD19-His, and the EC50 was 0.370 nM.

Co-incubation of Blinatumomab with Jurkat cells, then with the addition of hu-CD19-HEK293 cells for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Blinatumomab was able to activate the NF-AT signaling pathway.

-80°C for 2 years under sterile conditions；-20°C for 1 year under sterile conditions；Avoid repeated freeze-thaw cycles.